Adult Immunization Allergy & Immunology Cardiology Dermatology Endocrinology Gastroenterology Infectious Disease Men’s Health Nephrology Neurology Pain Management Pediatric Immunization Pediatrics Psychiatry Pulmonology Rheumatology Screening Women’s Health

Billing and Collections Career Planning Coding and Documentation Concierge Medicine Cybersecurity EHRs Investing Patient Relations Personal Finance Practice Management Remote Patient Monitoring Staffing Technology Telehealth Value-based Care

Unmet Needs in Managing MDD Interpreting Thyroid Function Tests Using Thyroid Lab Tests Testing & Screening to Optimize Men's Health

Empowering Early Intervention: Navigating Treatments for Delaying T1D Progression, Insights from Pediatric Endocrinology of North Texas : Episode 9

Expert Opinions into the Range of Teplizumab Infusion Locations, Insurance Coverage Hurdles, and the Approval Process

August 2, 2024

Jennifer D. Goldman, RPh, PharmD, CDCES, BC-ADM, FCCP
Amy Burton, MD

Opinion

Video

Focusing on logistical matters as it pertains to teplizumab administration, the panel discusses infusion site considerations, insurance coverage hurdles, and the process of getting patients approved.

EP: 1.Navigating T1D: Mitigating Burden and Monitoring Disease Progression

EP: 2.T1D Staging: The Clinical Importance of Early Recognition

EP: 3.Engaging the Audience: Polling on Primary Populations and Community Perspectives in T1D Care

EP: 4.T1D Antibody Screening: Identifying High-Risk Populations

EP: 5.Role of Teplizumab: First Approved Treatment for Delaying T1D Stage Progression

EP: 6.TN-10 Study Analysis: Expert Perspectives on Key Efficacy and Safety Data

EP: 7.Exploring Screening and Real-World Use of Teplizumab: Practical Insights and Clinical Experiences

EP: 8.Teplizumab Infusion Protocol: Details on the 14-Day Process and Comprehensive Monitoring Overview

EP: 9.Expert Opinions into the Range of Teplizumab Infusion Locations, Insurance Coverage Hurdles, and the Approval Process

EP: 10.Final Thoughts on Strategies for Managing and Monitoring Patients Receiving Teplizumab

Related Videos

New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time

Related Content

More than Half of US Adults Eligible for Semaglutide: Daily Dose / image credit: ©New Africa/AdobeStock

More than Half of US Adults Eligible for Semaglutide: Daily Dose

Sydney Jennings

December 9th 2024

Your daily dose of the clinical news you may have missed.

Man With Newly Diagnosed Type 2 Diabetes: What HbA1c Goal-And How to Get There?

Edward J. Shahady, MD

The patient, an active 49-year-old man, had an HbA1c of 8.6 after diabetes was first diagnosed. It’s now 7.6 with metformin and lifestyle measures. Is the current A1c goal adequate, or should you treat more aggressively?

More than Half of US Adults May Be Eligible for Semaglutide Therapy / image credit Dhruv Kazi, MD, MSc, MS Smith Center for Outcomes Research in Cardiology

More than Half of US Adults May Be Eligible for Semaglutide Therapy, Accordng to New Estimates

November 21st 2024

Millions of US adults could benefit from semaglutide treatment for diabetes, obesity, and/or CV disease but insurance isn't guaranteed and the drug is costly.

Challenging Case: A Patient With Hypoglycemia and High HbA1c

Challenging Case: A Patient With Hypoglycemia and High HbA1c

Edward J. Shahady, MD

Hypoglycemia in type 2 diabetes patients can be the result of insulin or sulfonylureas.

Data Published on Sotagliflozin Used to Reduce HbA1c in Adults with Type 1 Diabetes and Kidney Disease / image credit David Cherney UHN Research

Data Published on Sotagliflozin Used to Reduce HbA1c in Adults with Type 1 Diabetes and Kidney Disease

November 7th 2024

The data, published in JASN, were presented last week to an FDA advisory committee considering recommending sotagliflozin as an adjunct to insulin in adults with T1D and CKD.

Sotagliflozin Setback: Cautionary FDA AdComm Vote Reflects Continued Concern for Negative Risk/Benefit Ratio in T1D with CKD / image credit ©Tada Images/stock.adobe.com

Sotagliflozin Setback: Cautionary FDA AdComm Vote Reflects Continued Concern for Negative Risk/Benefit Ratio in T1D with CKD

November 1st 2024

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 11 to 3 against recommending the SGLT1/SLGT2 inhibitor to treat adults with T1D and CKD.

Related Content

More than Half of US Adults Eligible for Semaglutide: Daily Dose / image credit: ©New Africa/AdobeStock

More than Half of US Adults Eligible for Semaglutide: Daily Dose

Sydney Jennings

December 9th 2024

Your daily dose of the clinical news you may have missed.

Man With Newly Diagnosed Type 2 Diabetes: What HbA1c Goal-And How to Get There?

Edward J. Shahady, MD

The patient, an active 49-year-old man, had an HbA1c of 8.6 after diabetes was first diagnosed. It’s now 7.6 with metformin and lifestyle measures. Is the current A1c goal adequate, or should you treat more aggressively?

More than Half of US Adults May Be Eligible for Semaglutide Therapy / image credit Dhruv Kazi, MD, MSc, MS Smith Center for Outcomes Research in Cardiology

More than Half of US Adults May Be Eligible for Semaglutide Therapy, Accordng to New Estimates

November 21st 2024

Millions of US adults could benefit from semaglutide treatment for diabetes, obesity, and/or CV disease but insurance isn't guaranteed and the drug is costly.

Challenging Case: A Patient With Hypoglycemia and High HbA1c

Challenging Case: A Patient With Hypoglycemia and High HbA1c

Edward J. Shahady, MD

Hypoglycemia in type 2 diabetes patients can be the result of insulin or sulfonylureas.

Data Published on Sotagliflozin Used to Reduce HbA1c in Adults with Type 1 Diabetes and Kidney Disease / image credit David Cherney UHN Research

Data Published on Sotagliflozin Used to Reduce HbA1c in Adults with Type 1 Diabetes and Kidney Disease

November 7th 2024

The data, published in JASN, were presented last week to an FDA advisory committee considering recommending sotagliflozin as an adjunct to insulin in adults with T1D and CKD.

Sotagliflozin Setback: Cautionary FDA AdComm Vote Reflects Continued Concern for Negative Risk/Benefit Ratio in T1D with CKD / image credit ©Tada Images/stock.adobe.com

Sotagliflozin Setback: Cautionary FDA AdComm Vote Reflects Continued Concern for Negative Risk/Benefit Ratio in T1D with CKD

November 1st 2024

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 11 to 3 against recommending the SGLT1/SLGT2 inhibitor to treat adults with T1D and CKD.

Terms and Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.